DBV Technologies S.A.
- Open
- 14.34
- Day high
- 14.47
- Day low
- 14.04
- Prev close
- 14.57
- Volume
- 227K
- Mkt cap
- $863M
- P/E (TTM)
- —
- EPS (TTM)
- —
- P/B
- 5.4
- P/S
- —
- Yield
- —
- Per share
- —
DBV Technologies S.A. (DBVT) is a Healthcare company listed on NASDAQ. The stock is up 51% over the past year.
DBV Technologies S.A. (DBVT) financials & analyst ratings
Fundamentals (TTM)
Analyst consensus · 2 analysts
Source: exchange market data + company filings. Figures are trailing-twelve-month or as most recently reported. For informational purposes only — not investment advice.
DBVT earnings date, history & EPS estimates
| Report date | EPS est | EPS actual | Surprise | Revenue | Rev. surprise |
|---|---|---|---|---|---|
| Jul 16, 2026 | $-0.12 | $-0.49 | -307.5% | $800196 | -10.9% |
| Apr 30, 2026 | $-0.14 | $-0.56 | -300.0% | $1M | -4.9% |
| Mar 26, 2026 | $-1.30 | $-1.15 | +11.5% | $577590 | -60.5% |
| Oct 28, 2025 | $-1.45 | $-1.20 | +17.2% | $3M | +204.5% |
| Jul 29, 2025 | $-0.21 | $-1.55 | -638.1% | $2M | +129.6% |
| Apr 30, 2025 | $-0.24 | $-0.26 | -8.3% | $906408 | +81.3% |
| Mar 27, 2025 | $-2.00 | $-1.20 | +40.0% | $553101 | +19.5% |
| Mar 7, 2024 | $-0.32 | $-0.12 | +62.5% | $2M | -4.6% |
| May 4, 2023 | $-0.50 | $-0.22 | +56.0% | $2M | -9.5% |
| Mar 2, 2023 | $-2.30 | $-2.30 | +0.0% | $-1M | -193.3% |
| Nov 3, 2022 | $-0.32 | $-0.18 | +43.8% | $2M | -19.2% |
| Aug 1, 2022 | $-1.70 | $-1.80 | -5.9% | $2M | -6.2% |
DBVT insider trading activity (SEC Form 4)
| Date | Insider | Type | Shares | Price |
|---|---|---|---|---|
| Feb 2, 2026 | Mohideen Pharisofficer: Chief Medical Officer | Sell | 534 | $4.86 |
| Jan 14, 2026 | BAKER BROS. ADVISORS LPdirector | Option | 25,005,240 | — |
| Jan 14, 2026 | BAKER BROS. ADVISORS LPdirector | Option | 2,299,656 | — |
| Dec 19, 2025 | EPIC Bpifranceother: Member of 10% owner group | Sell | 1,292,103 | $4.19 |
| Dec 19, 2025 | EPIC Bpifranceother: Member of 10% owner group | Sell | 2,036,990 | $4.84 |
| Dec 19, 2025 | EPIC Bpifranceother: Member of 10% owner group | Sell | 40,000 | $5.28 |
| Nov 25, 2025 | Mohideen Pharisofficer: Chief Medical Officer | Grant | 44,000 | — |
| Nov 25, 2025 | Mohideen Pharisofficer: Chief Medical Officer | Grant | 253,000 | $2.90 |
| Nov 25, 2025 | Mohideen Pharisofficer: Chief Medical Officer | Sell | 6,496 | $2.88 |
| Nov 25, 2025 | Mohideen Pharisofficer: Chief Medical Officer | Sell | 1,624 | $2.77 |
| Nov 24, 2025 | Boucinha Virginieofficer: Chief Financial Officer | Grant | 192,000 | $2.90 |
| Nov 24, 2025 | Boucinha Virginieofficer: Chief Financial Officer | Grant | 32,000 | — |
| Nov 24, 2025 | Trapp Kevin Michaelofficer: Chief Commercial Officer | Grant | 316,250 | $2.90 |
| Nov 24, 2025 | Trapp Kevin Michaelofficer: Chief Commercial Officer | Grant | 55,000 | — |
| Nov 24, 2025 | Tasse Danieldirector, officer: CHIEF EXECUTIVE OFFICER | Grant | 964,000 | $2.90 |
Source: DBVT SEC Form 4 filings, latest Feb 2, 2026. For informational purposes only — not investment advice.
See the full DBVT insider & 13F page →DBV Technologies S.A. company profile
Overview
DBV Technologies S.A. (NASDAQ:DBVT) is a French clinical-stage biopharmaceutical company founded in 2002 and headquartered in Montrouge, France. The company went public on NASDAQ in October 2014 and specializes in developing epicutaneous immunotherapy treatments, which deliver therapeutic compounds through the skin rather than through injections or oral medications. DBV Technologies is primarily focused on developing treatments for food allergies, with its lead product candidate being Viaskin Peanut for treating peanut allergies in children and toddlers.
Business
DBV Technologies operates in the specialized field of epicutaneous immunotherapy, a novel approach to treating allergies by delivering therapeutic agents through patches applied to the skin. This method represents an alternative to traditional allergy treatments like oral immunotherapy (eating small amounts of allergens) or subcutaneous injections. The company's core technology platform centers around Viaskin patches, which are adhesive patches containing allergen proteins that are applied to the patient's skin. These patches work by delivering controlled amounts of allergens through the skin to immune cells, gradually training the immune system to become less reactive to specific allergens over time. This process, called desensitization, can potentially reduce the severity of allergic reactions or increase the threshold amount of allergen that triggers a reaction. The company's primary product pipeline includes several Viaskin variants targeting different food allergies. Viaskin Peanut is the most advanced candidate, having completed Phase III clinical trials for treating peanut allergies in children aged 4-11 years and adults. The company is currently conducting additional Phase III studies (VITESSE trial) for children aged 4-7 years and developing programs for toddlers aged 1-3 years. Viaskin Milk is in Phase I/II trials for treating cow's milk protein allergy, while Viaskin Egg remains in preclinical development for hen's egg allergies. Beyond food allergies, DBV Technologies has early-stage research programs exploring treatments for autoimmune conditions like Crohn's disease, celiac disease, and type I diabetes, as well as vaccine applications including a booster vaccine for Bordetella pertussis and a respiratory syncytial virus vaccine. The company previously had a collaboration with Nestlé Health Science to develop MAG1C, a diagnostic patch test for cow's milk protein allergy, but this partnership was terminated in 2023 to focus resources on core programs.
Revenue model
DBV Technologies operates on a traditional biopharmaceutical business model focused on developing and commercializing proprietary therapeutic products. The company currently generates minimal revenue, with only $2.6 million in 2024 revenue primarily from research collaborations and licensing agreements, as none of its products have received regulatory approval for commercial sale. The company's future revenue model will depend on successfully bringing Viaskin products to market through regulatory approval processes. Once approved, DBV Technologies would generate revenue through direct product sales to healthcare providers, hospitals, and specialty allergy clinics. The target customers would be allergists, pediatricians, and other healthcare professionals treating patients with food allergies, with patients or their insurance providers ultimately paying for the treatment. The company's financial performance is heavily influenced by clinical trial costs, regulatory approval timelines, and the competitive landscape in allergy treatments. Clinical development expenses represent the largest component of operating costs, with over 90% of operational cash used for Viaskin Peanut clinical development programs. The lengthy and expensive nature of pharmaceutical development creates significant cash burn, with the company using over $100 million in operating cash flow in 2024. Key factors that could impact future margins include manufacturing scale economies once commercial production begins, pricing negotiations with insurance providers and healthcare systems, competition from other allergy treatment modalities like oral immunotherapies or biologics, and the breadth of patient populations that achieve regulatory approval. The epicutaneous delivery method may command premium pricing due to its convenience and safety profile compared to injection-based treatments, but this advantage could be offset by competitive pressures from established oral immunotherapy products already on the market.
Competitive moat
DBV Technologies possesses a moderate competitive moat based primarily on its proprietary epicutaneous immunotherapy technology and intellectual property portfolio. The company's Viaskin patch platform represents a differentiated approach to allergy treatment that offers potential advantages over existing therapies, including improved safety profiles due to lower systemic exposure and greater convenience for patients, particularly children who may resist oral medications or injections. The company's intellectual property estate provides some protection, with patents covering the epicutaneous delivery system, specific patch formulations, and manufacturing processes. However, this moat faces several challenges. The patent protection is time-limited and may not prevent competitors from developing alternative patch-based delivery systems or improving existing oral immunotherapy approaches. Additionally, large pharmaceutical companies with greater resources could potentially develop competing epicutaneous technologies or acquire smaller competitors in the space. The regulatory approval process creates temporary barriers to entry, as DBV Technologies has invested years and significant capital in clinical trials that competitors would need to replicate. However, this advantage diminishes over time as other companies advance their own programs. The company faces direct competition from approved oral immunotherapy products like Palforzia (AR101) for peanut allergies, which already has market presence and physician familiarity. The specialized nature of allergy treatment and the need for physician expertise in administering immunotherapy provides some market protection, but this is not unique to DBV Technologies. The company's moat is further weakened by its current lack of approved products and ongoing cash burn, which creates execution risk and potential vulnerability to better-funded competitors. Overall, while DBV Technologies has carved out a defensible niche in epicutaneous immunotherapy, the moat is not particularly wide and faces ongoing competitive and technological threats.
Risks & safety
DBV Technologies presents significant financial risk with a narrow margin of safety for investors: • Cash burn and solvency: The company burned $104.5 million in operating cash flow during 2024, with cash declining from $141.4 million to $32.5 million. At current burn rates, the company has limited runway extending into early 2025, creating near-term solvency concerns. • Current liquidity position: Current ratio of 1.43 indicates modest liquidity, but with $31.1 million in current liabilities against $32.5 million in cash, the company has little financial cushion for unexpected expenses or trial delays. • Debt levels: Relatively low debt-to-equity ratio of 0.28 provides some balance sheet flexibility, though total liabilities of $38.3 million represent a significant portion of the company's $65.7 million in total assets. • Valuation metrics: Trading at 2.2x book value with negative earnings makes traditional valuation difficult. The company's $250 million market capitalization appears high relative to its current financial position and lack of approved products. • Revenue generation: Minimal revenue of $2.6 million in 2024 provides virtually no financial support for operations, making the company entirely dependent on successful clinical outcomes and future financing. • Clinical and regulatory risks: Success depends entirely on FDA approval of Viaskin Peanut, with no backup revenue sources if trials fail or approval is delayed beyond current cash runway.
Recent development
Over the past few years, DBV Technologies has focused its strategic efforts on advancing Viaskin Peanut through late-stage clinical development while streamlining operations to extend its financial runway. The company has pursued a dual-track approach for Viaskin Peanut, developing separate programs for two distinct age groups: toddlers aged 1-3 years and children aged 4-7 years, based on encouraging efficacy signals observed in younger patients. A significant strategic pivot occurred in 2023 when the company terminated its collaboration with Nestlé Health Science on the MAG1C diagnostic patch to concentrate resources on its core Viaskin Peanut programs. This decision reflected management's focus on maximizing the probability of success for their lead asset rather than pursuing multiple development paths simultaneously. The company has been actively engaged with the FDA to address regulatory requirements, particularly around supplemental safety studies called COMFORT Toddlers and COMFORT Children. These additional studies were requested by regulators to provide more comprehensive safety data before potential approval. Management has also been working with the FDA on labeling strategies that account for "patch wear time experience," recognizing that real-world usage patterns may differ from controlled clinical trial conditions. In 2024, the company completed enrollment for its VITESSE Phase III trial in the 4-7 year age group and continued advancing the toddler program, which has shown particularly promising results with some patients able to consume significant amounts of peanut protein after treatment. The company has implemented cost-saving measures to extend its cash runway while maintaining progress on these critical trials, demonstrating disciplined capital allocation in the face of financing constraints.
DBVT company profile · for informational purposes only — not investment advice.
Track DBVT with Drillr
SEC filings, earnings calls, insider activity, alt-data signals — all queryable through Drillr's AI terminal and MCP API.
Try Drillr for free